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This paper presents an experience of thirty con-
secutive patients with hepatic colorectal metastases
who were treated with hepatic cryotherapy and
subsequent hepatic arterial infusion (HAI) che-
motherapy using 5 FU.
Patients with colorectal metastases confined to the
liver but not suitable for resection, and with liver
involvement of less than 50% were offered the
treatment. Prospective documentation of all patients
was undertaken with data being recorded on a
computerised database.
Patients had a median of 6 (2-15) lesions with
sizes ranging from 1-12 cm. There was no 30day
mortality. Postoperative complications developed in
8 patients but were followed by full recovery in all
instances. Side effects from chemotherapy occured
in 23% of cycles. Twenty seven patients have died.
Median survival from the time of cryotherapy was
18.2 months (7-34), or 23months (9-44) from
diagnosis of liver lesions.
Hepatic cryotherapy with subsequent arterial
chemotherapy is safe and well tolerated. The results
suggest survival of patients with colorectal hepatic
metastases can be improved by the use of this
modality of treatment.
Keywords: Colorectal cancer, hepatic cryotherapy, liver meta-
stases, hepatic artery chemotherapy
INTRODUCTION
Colorectal cancer is a common disease in New
Zealand with approximately 2000 new cases
being registered annually. Liver metastases are
found at diagnosis in some 25% of patients with
colorectal cancer [1] and another 25-40% will
eventually develop metastases [2]. Median sur-
vival for patients with untreated colorectal
hepatic metastases is 6 to 8 months from
diagnosis, and less than 2% survive for 5 years
[3]. Surgical resection of liver metastases confers
a median survival of over two years and a 25-
52% five-year survival rate [4-6]. However,
because of the number and/or location of
metastases within the liver, fewer than 25% of
patients are candidates for resection [7].
Cryotherapy with in-situ destruction of tumours
is a possible treatment option. As a focal
treatment, it spares more normal liver tissue
than resection, thus allowing multiple lesions
affecting both lobes of the liver to be treated.
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Good results have been achieved in patients
with hepatocellular carcinoma [8] and encoura-
ging results have been reported for patients with
colorectal liver metastases [9 11].
Systemic chemotherapy regimens have been
used for many years to treat metastatic colorectal
cancer [12, 13]. The most active agent in this
context is 5 fluorouracil (5 FU). The addition of
folinic acid, which augments the cytotoxic
activity of 5FU and spares some toxicity,
produces higher response rates than 5 FU alone.
However, response rates remain less than 20% at
the cost of significant systemic toxicity and there
is little or no impact on survival [13, 14]. Hepatic
arterial infusion (HAI) chemotherapy, in con-
trast, appears to be a more effective modality of
treatment for non-resectable metastatic disease
confined to the liver [15, 16]. In most studies,
well over one third of the patients respond to
this chemotherapy, and a median survival of
12-25months has been reported [16-18]. A
treatment protocol combining the potential
benefits of hepatic cryotherapy and hepatic
arterial 5FU has been employed at The Wake-
field Clinic since 1991 to treat patients with non-
resectable colorectal hepatic metastases. This
report presents the experience in the first 30
consecutive patients so treated.
MATERIALS AND METHODS
Thirty patients with colorectal liver metastases
underwent treatment between October 1991 and
October 1994 at The Wakefield Clinic. They
included 22 males and 8 females with a median
age of 55years (range 24-78). Preoperative
investigations included chest X-ray, abdominal
CT Scan, routine blood tests and CEA. Patients
were selected on the following criteria: (1) they
had metastatic colorectal cancer confined to the
liver, (2) the disease was unsuitable for resection
because of the number and/or distribution of
lesions within the liver, (3) they were considered
fit to undergo a major surgical procedure and (4)
the disease was manageable with regard to the
number of lesions (up to 10-15), their size (not
more than one lesion > 5 cm), and less than 50%
of the liver was involved. The treatment was
carried out within a few weeks of evaluation at a
time when most of the patients were asympto-
matic. The liver metastases were synchronous in
24 patients and metachronous in 6. The original
bowel tumour was Dukes C in 23 patients and
Dukes B in 7. A median number of 6 lesions per
patient were treated (range 2-15), and the size
of lesions ranged from 1-12 cm.
The abdomen was explored through a bilat-
eral subcostal incision under general anaesthetic
and epidural. The liver and upper abdomen
were thoroughly examined by palpation and
intraoperative ultrasound (IOUS). Cholecystec-
tomy was routinely carried out. Cryotherapy
was performed using an LCS II system (Cryo-
tech Ltd, UK) with either a 5mm or 9mm
needle probe or flat probe through which liquid
nitrogen was circulated at -196C. Intraopera-
tive ultrasound was used to detect occult liver
tumours, guide the cryoprobe into lesions and
monitor the freezing process. The aim was to
freeze each lesion completely with a 5-10 mm
margin of surrounding liver tissue. An arterial
Infuse-a port (Infusaid USA) was placed sub-
cutaneously over the inferior anterolateral as-
pect of the right rib cage. The catheter tip was
positioned in the gastroduodenal artery at its
origin from the common hepatic artery. Com-
plete hepatic perfusion was confirmed by inject-
ing 2- 5 mL methylene blue through the port. In
the event of incomplete liver perfusion, a second
hepatic artery was sought. If feasible this was
anastomosed to the hepatic artery already
identified. Alternatively a second catheter from
a separate port was inserted into the anomalous
artery by a side branch created by division of the
artery and end-to-side re-anastomosis. How-
ever, we recently started simply ligating the
second artery and noticed a complete hepatic
perfusion after reinjecting methylene blue. The
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(100IU/mL). Avoidance of extrahepatic perfu-
sion was accomplished by ligating the proximal
branches of the gastroduodenal artery.. All
patients received a single prophylactic dose of
1.0 g IV Rocephin(R) (Ceftriaxone) and most
received intra-operative IV mannitol 10-15 g
to encourage good urine output. Patients were
monitored for 24 hours post-operatively in the
Intensive Care Unit.
HAI chemotherapy was usually started within
4 weeks of surgery. Patients were generally
maintained as outpatients for this procedure
and were encouraged to pursue normal activities.
The regimen entailed 50 mg Folinic acid bolus via
the port, followed by 5 FU 1.0 g each 24 hours for
4 days delivered by a disposable, portable pump
(Baxter Healthcare Ltd, Singleday infusor
PC1071). Cycles were planned every 4 weeks
for a total of six cycles. If after 6 cycles CT
Scanning revealed residual hepatic disease, HAI
was continued. Treatment was discontinued if
unacceptable side effects developed, hepatic
artery thrombosis occured, or CT Scanning
revealed unequivocal major disease progression.
Patients were re-evaluated at 3 monthly inter-
vals with CT Scan of the liver, chest X-ray and
routine blood tests including CEA. Disease
status was determined radiologically as either
tumour progression (an increase in size or
number of metastases), stable disease or tumour
regression. Disease assessments were based on a
comparison between sequential 3monthly CT
Scans. On this basis patients may have been
regarded as having disease progression at one
point in time, yet the extent of hepatic involve-
ment may still have been less than that prior to
cryotherapy.
Fisher Exact test was used for statistical
analysis.
RESULTS
The surgery was well tolerated in most patients.
It entailed a median operating theatre time of
5hours. The number of lesions treated per
patient varied from 2 to 15 (median 6). Nineteen
(63.3%) patients were thought to have complete
cryotherapy (cryo destruction of all macroscopic
tumours), whereas in 11 (36.7%) patients,
cryotherapy was considered incomplete. Crack-
ing of the ice-ball upon thawing occured with
the larger lesions resulting in bleeding but this
was controlled with pressure and suture. Intra-
operative blood loss was in the range 100-
7240mL (median 1400mL) and 17 (56.7%)
patients required blood transfusion. Postopera-
tive complications developed in 8 patients.
These included pleural effusion in 2, renal
failure in 1, liver abscess in 1, wound infection
in 1, myocardial infarction and atrial fibrillation
in 1, congestive heart failure in 1, and skin burn
in another patient. All patients recovered fully
and there was no 30 day mortality. The median
hospital stay was 9.5 days (range 6- 23).
Two patients did not receive (HAI) chemo-
therapy for technical reasons related to port
placement. Of the other 28 patients, 9 received 6
cycles, 7 received more than 6 cycles (7-27), and
12 received less than 6 cycles. A total of 209
cycles were given. Side effects developed in 48
(23%) cycles. These were considered mild in
8.6%, moderate in 9.1%, and severe in 5.3%. Mild
side effects consisted of lethargy and nausea.
Moderate side effects entailed nausea with
marked epigastric pain. These were controlled
either with medications or by reducing the dose
of chemotherapy. In only 2 patients was chemo-
therapy discontinued due to unacceptable side
effects. No instances of systemic toxicity with
bone marrow depression, stomatitis, or diar-
rhoea were observed.
Preoperative CEA measurement was carried
out in 26 patients and in 23 of them (88.5%) it
was elevated. At 3 months postoperative follow-
up 14/22 patients (64%) showed a reduction in
CEA levels. In 7 of these it returned to normal
levels. At 6 months 10/20 patients (50%) con-
tinued to have reduced levels. Twenty five of the
27 patients who have died has rising CEA prior100 R.S. STUBBS et al.
to their death. In the other 2 cases data were
insufficient to permit comment. One of the three
living patients has a normal CEA level 45
(a)
(d)
FIGURE Series of CT Scans of a patient who had 9
metastatic liver lesions showing the changes in these
following cryotherapy; (a) Peroperative CT Scan; (b) Post-
operative scan at 6 months showing the lesions reducing in
size; (c) Scan at 9 months showing the lesions were static; (d)
Scan at 12 months showing the appearance of new lesions.
When compared with previous scan, the disease was
described as "progressed", however, hepatic involvement
was still less than that of the original disease shown in (a).
(b)
(c)
months after cryotherapy. The other two cases
have rising levels. One of them was found to
have a solitary recurrent lesion in the right lobe
of the liver with no evidence of extrahepatic
spread of the disease. Right hepatectomy was
subsequently performed 22 months after
cryotherapy of 3 lesions. Now she is disease
free 13 months after hepatic resection, and
35 months from cryotherapy.
At 6 months follow-up 19 patients showed
static disease or regression on CT Scanning. In
one of these all treated lesions had disappeared.
At 9 months hepatic disease progression was
evident in 19 patients, but 11 continued to have
regression or stable disease. Of the 19 with
disease progression 11 (57.9%) had received less
than the planned 6 cycles of arterial chemother-
apy, whereas 2 of the 11 (18.1%) patients with no
evidence of progression had received less than 6
cycles of arterial chemotherapy. This difference
is not statistically significant. At 12 months
follow-up 8 patients had died, 18 had disease
progression, and 4 continued to have static
disease. However, as previously mentioned,HEPATIC CRYOTHERAPY AND REGIONAL CHEMOTHERAPY 101
patients who were regarded at one stage of
follow-up as having disease progression, fre-
quently still had less disease than that shown by
CT Scan prior to cryotherapy. Figure la-d
demonstrate the changes seen in one patient at
different stages of follow-up.
At the time of death 8/27 patients (29.6%) had
isolated liver disease as judged clinically and by
chest X-ray and abdominal CT Scanning. In 4 of
these hepatic arterial chemotherapy had been
curtailed for various reasons. All other patients
had abdominal disease (including local recur-
rence) and/or extra-abdominal disease. Extra-
abdominal spread was to the lungs in all
patients except in 3 who had bone metastases.
Eight patients died within 12 months of
cryotherapy, 6 of whom (75%) received less than
the planned 6 cycles of chemotherapy. Twenty
two survived longer than 12months after
cryotherapy ofwhom seven (31.8%) received less
than 6 Cycles of chemotherapy. This difference is
statistically significant (P < 0.05). There were no
obvious differences in the nature and extent of
disease prior to treatment in those who did or did
not complete 6 cycles of chemotherapy.
Patients were followed till death or to
November 1996. Median survival is 18.2 months
(range 7-34) from cryotherapy or 23 months
(range 9-44) from diagnosis of liver metastases.
Twenty seven patients have died. Three patients
are currently alive, 45, 42, and 35 months after
treatment. One of them has a normal CEA and
no evidence of tumour on abdominal CT Scan or
chest X-ray 45 months after treatment of four
metastatic sites within the liver.
DISCUSSION
In patients with solitary liver lesions or lesions
confined to one side of the liver, resection is the
treatment of choice. A number of studies have
demonstrated that this approach is not only safe
but also potentially curative especially in pa-
tients with less than four metastases and a node-
negative primary lesion [5, 19, 20]. In contra-
distinction to most types of liver metastases
those from colorectal cancer can occur without
tumour growth elsewhere [1, 21, 22].
Unfortunately, even in patients with meta-
stases confined to the liver, the majority are not
suitable for resection because of the number
and/or distribution of these metastases within
the liver. Systemic and regional chemotherapy
are possible treatment options. In spite of
moderately extensive world experience with
hepatic arterial chemotherapy, the use of this
modality has not gained general acceptance.
There is reason however to believe it should be
more widely considered for patients with meta-
static colorectal cancer in the liver [17]. Regional
perfusion delivers a high concentration of drug
to the liver without incurring systemic dose-
limiting toxicity. This is particularly so when
drugs which are cleared on first pass through
the liver such as 5FU and fluorodeoxyuridine
(FUDR) are employed. Prospective randomised
trials comparing HAI chemotherapy with sys-
temic chemotherapy have shown response rates
of 48-62% with HAI compared to less than 20%
for intravenous therapy [17, 18]. It is often stated
that this improved response rate does not
translate into survival advantage. However,
there is evidence to suggest survival is improved
[17, 18, 23]. All trials have confirmed the higher
response rate of tumour to arterial chemother-
apy and have shown an associated numerical
survival advantage. In the largest study the
survival advantage was statistically significant
[24]. In two trials crossover between treatment
groups was allowed and patients who did not
respond to systemic chemotherapy were
switched to HAI chemotherapy to which many
responded [25, 26]. The role of adjuvant HAI
therapy after liver resection has also been
examined in a randomised trial [27]. Although
the study involved only small numbers of
patients, there was a trend toward increased
survival in patients with resection plus HAI
chemotherapy. In another single-arm study102 R.S. STUBBS et al.
using adjuvant HAI chemotherapy after liver
resection a lower incidence of recurrent disease
was found when comparison was made with
historical controls treated with surgerY alone
[28]. Thus the data suggest that local disease in
the liver may be controllable by HAI.
A number of interstitial (focal) treatment
modalities have been advocated for patients
with hepatocellular carcinoma and hepatic me-
tastases. These includes cryotherapy, alcohol
injection, low power laser hyperthermia and
interstitial radiotherapy [29]. In these modalities
the therapeutic stimulus is delivered directly to a
selected site of intended tissue damage, with
preservation of the surrounding normal tissue.
The effects on living tissue of sub-zero tempera-
tures is reasonably well understood [30, 31] and
if tempertures below -20C are attained tissue
destruction is almost always achieved. Cryother-
apy of large solid tumours has been made
possible following the development of appro-
priate delivery systems and probes utilising
liquid nitrogen at -196C. The LCS II (Cryotech,
UK) is one such system currently available. The
liver is an ideal organ for treatment by this
modality because a margin of normal tissue can
be destroyed with reasonable impunity. Further-
more intraoperative ultrasound can be employed
to demonstrate the lesions within the liver and
also the frozen "ice-ball" created by the freezing
process. In this way a degree of precision can be
applied to the treatment. The efficacy of the
modality was first established following the
report of the use of cryosurgery in hepatocellular
carcinoma in which the results achieved in
lesions less than 5 cm in diameter were compar-
able to surgical resection [8]. Subsequently a
number of encouraging.reports appeared in the
literature concerning its use in the treatment of
colorectal hepatic metastases [9-11].
In the present series, patients were not
candidates for liver resection because they had
a median of 6 hepatic lesions. Cryoablation was
used to destroy these lesions and HAI chemo-
therapy was added in the hope of controlling
remaining microscopic and on occasions macro-
scopic tumour.
The procedure was well tolerated with no
30 day mortality and few serious postoperative
complications. Likewise side effects following
arterial chemotherapy occured in only 23% of
cycles. These were relatively minor and easily
controlled with medications or by reducing the
dose of chemotherapy. These side effects were
due to local effects of chemotherapy reaching the
upper gut from small unrecognised arteries
supplying the stomach, duodenum or pancreas.
No systemic toxicity was seen in any patient.
Cholecystectomy was routinely performed to
prevent chemical cholecystitis [18].
Initial control of the hepatic disease was
indicated by the fact that 64% of patients
showed a reduction in CEA levels at 3 months
postoperative follow-up. In 7 of them it returned
to normal. At 6 months follow-up 50% of them
continued to have reduced levels. Failure to
achieve reduction in CEA levels may be due to
the incomplete cryotherapy in some patients or
to occult hepatic or extrahepatic disease. Control
of the disease was also noticed by follow up CT
Scanning. At 6 months, only 11 patients had
disease progression. At 9 months, 19 patients
had disease progression and at 12months
follow-up, the disease was progressive in 26
patients. However, as previously mentioned,
patients who were regarded at one stage of
follow up as having disease progression, fre-
quently still had less disease than that shown by
CT Scan prior to cryotherapy (Fig. 1).
Eight patients died within 12 months of
cryotherapy, 6 of whom (75%) received less
than the planned 6 cycles of chemotherapy.
Twenty two survived longer than 12 months
after cryotherapy of whom 7(31.8%) received
less than 6 cycles of chemotherapy. This differ-
ence is statistically significant (P < 0.05) suggest-
ing the addition of HAI chemotherapy confered
additional benefit over cryotherapy alone. As
mentioned previously there were no obvious
differences in the nature and extent of diseaseHEPATIC CRYOTHERAPY AND REGIONAL CHEMOTHERAPY 103
prior to treatment in those who did or did not
complete 6 cycles of chemotherapy.
From the data presented some control of liver
metastases was achieved. The median survival
of 18.2 months from cryotherapy or 23 months
from diagnosis is better than reported median
survival of 6-8 months for untreated patients
with similar disease [3, 19]. These results are
encouraging and indicate that this combination
of treatment modalities merits further use and
investigation in patients with colorectal hepatic
metastases who are otherwise unsuitable for
resection.
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